Patient characteristics of the overall cohort, and by relapse status
| . | All patients (N = 8675) . | No second-line treatment (n = 7000) . | Second-line treatment (n = 1675) . | Standardized difference . |
|---|---|---|---|---|
| Age at cohort entry, y | ||||
| Median (Q1-Q3) | 68 (57-76) | 68 (57-77) | 67 (57-75) | 0.08 |
| 18-60, n (%) | 2585 (29.8) | 2063 (29.5) | 522 (31.2) | 0.04 |
| 60-69, n (%) | 2179 (25.1) | 1705 (24.4%) | 474 (28.3) | 0.09 |
| 70-79, n (%) | 2463 (28.4) | 2016 (28.8) | 447 (26.7) | 0.05 |
| ≥80, n (%) | 1448 (16.7) | 1216 (17.4) | 232 (13.9) | 0.10 |
| Sex, n (%) | ||||
| Female | 3851 (44.4) | 3180 (45.4) | 671 (40.1) | 0.11 |
| Income quintile, n (%) | ||||
| 1 | 1577 (18.2) | 1289 (18.4) | 285-289∗ | 0.03 |
| 2 | 1774 (20.4) | 1444 (20.6) | 330 (19.7) | 0.02 |
| 3 | 1713 (19.7) | 1350 (19.3) | 363 (21.7) | 0.06 |
| 4 | 1678 (19.3) | 1350 (19.3) | 328 (19.6) | 0.007 |
| 5 | 1914 (22.1) | 1550 (22.1) | 364 (21.7) | 0.01 |
| Rural residence, n (%) | 1124 (13.0) | 902 (12.9) | 218-222∗ | 0.01 |
| Cancer stage at diagnosis, n (%) | ||||
| I | 886 (10.2) | 800 (11.4) | 86 (5.1) | 0.23 |
| II | 971 (11.2) | 838 (12.0) | 133 (7.9) | 0.14 |
| III | 687 (7.9) | 510 (7.3) | 177 (10.6) | 0.12 |
| IV | 1891 (21.8) | 1393 (19.9) | 498 (29.7) | 0.23 |
| Missing | 4240 (48.9) | 3459 (49.4) | 781 (46.6) | 0.06 |
| Days from diagnosis to treatment, n (%) | ||||
| 0-28 | 2459 (28.3) | 1914 (27.3) | 545 (32.5) | 0.11 |
| 29-56 | 4046 (46.6) | 3324 (47.5) | 722 (43.1) | 0.09 |
| ≥57 | 2170 (25.0) | 1762 (25.2) | 408 (24.4) | 0.02 |
| No. of cycles of frontline treatment | ||||
| Median (Q1-Q3) | 6 (4-6) | 6 (4-6) | 6 (5-6) | 0.04 |
| Noncancer ADGs | ||||
| Median (Q1-Q3) | 10 (8-13) | 10 (8-13) | 10 (8-13) | 0.01 |
| Frailty (ACG-based), n (%) | 1237 (14.3) | 1008 (14.4) | 229 (13.7) | 0.02 |
| Year initiated frontline therapy, n (%) | ||||
| 2012-2015 | 2968 (34.2) | 2319 (33.1) | 649 (38.7) | 0.12 |
| 2016-2019 | 3131 (36.1) | 2487 (35.5) | 644 (38.4) | 0.06 |
| 2020-2022 | 2576 (29.7) | 2194 (31.3) | 382 (22.8) | 0.19 |
| . | All patients (N = 8675) . | No second-line treatment (n = 7000) . | Second-line treatment (n = 1675) . | Standardized difference . |
|---|---|---|---|---|
| Age at cohort entry, y | ||||
| Median (Q1-Q3) | 68 (57-76) | 68 (57-77) | 67 (57-75) | 0.08 |
| 18-60, n (%) | 2585 (29.8) | 2063 (29.5) | 522 (31.2) | 0.04 |
| 60-69, n (%) | 2179 (25.1) | 1705 (24.4%) | 474 (28.3) | 0.09 |
| 70-79, n (%) | 2463 (28.4) | 2016 (28.8) | 447 (26.7) | 0.05 |
| ≥80, n (%) | 1448 (16.7) | 1216 (17.4) | 232 (13.9) | 0.10 |
| Sex, n (%) | ||||
| Female | 3851 (44.4) | 3180 (45.4) | 671 (40.1) | 0.11 |
| Income quintile, n (%) | ||||
| 1 | 1577 (18.2) | 1289 (18.4) | 285-289∗ | 0.03 |
| 2 | 1774 (20.4) | 1444 (20.6) | 330 (19.7) | 0.02 |
| 3 | 1713 (19.7) | 1350 (19.3) | 363 (21.7) | 0.06 |
| 4 | 1678 (19.3) | 1350 (19.3) | 328 (19.6) | 0.007 |
| 5 | 1914 (22.1) | 1550 (22.1) | 364 (21.7) | 0.01 |
| Rural residence, n (%) | 1124 (13.0) | 902 (12.9) | 218-222∗ | 0.01 |
| Cancer stage at diagnosis, n (%) | ||||
| I | 886 (10.2) | 800 (11.4) | 86 (5.1) | 0.23 |
| II | 971 (11.2) | 838 (12.0) | 133 (7.9) | 0.14 |
| III | 687 (7.9) | 510 (7.3) | 177 (10.6) | 0.12 |
| IV | 1891 (21.8) | 1393 (19.9) | 498 (29.7) | 0.23 |
| Missing | 4240 (48.9) | 3459 (49.4) | 781 (46.6) | 0.06 |
| Days from diagnosis to treatment, n (%) | ||||
| 0-28 | 2459 (28.3) | 1914 (27.3) | 545 (32.5) | 0.11 |
| 29-56 | 4046 (46.6) | 3324 (47.5) | 722 (43.1) | 0.09 |
| ≥57 | 2170 (25.0) | 1762 (25.2) | 408 (24.4) | 0.02 |
| No. of cycles of frontline treatment | ||||
| Median (Q1-Q3) | 6 (4-6) | 6 (4-6) | 6 (5-6) | 0.04 |
| Noncancer ADGs | ||||
| Median (Q1-Q3) | 10 (8-13) | 10 (8-13) | 10 (8-13) | 0.01 |
| Frailty (ACG-based), n (%) | 1237 (14.3) | 1008 (14.4) | 229 (13.7) | 0.02 |
| Year initiated frontline therapy, n (%) | ||||
| 2012-2015 | 2968 (34.2) | 2319 (33.1) | 649 (38.7) | 0.12 |
| 2016-2019 | 3131 (36.1) | 2487 (35.5) | 644 (38.4) | 0.06 |
| 2020-2022 | 2576 (29.7) | 2194 (31.3) | 382 (22.8) | 0.19 |
Reported as numbers and percentages, unless otherwise specified.
ADGs, aggregated diagnosis groups; Q1, first quartile; Q3, third quartile.
Refers to the use of a range of numbers to minimize the risk of reidentification, in accordance with ICES policies.